News from cyxone A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

06 Sep, 2019, 12:28 BST First Berlin Equity Research Publishes Independent Analysis of Cyxone

Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that the internationally renowned research company First Berlin Equity...


04 Sep, 2019, 13:55 BST Cyxone Explores Orphan Drug Designation for Rabeximod

Cyxone (publ), a Swedish biotechnology company in autoimmune diseases, today announced that the company's board of directors has decided to explore...


29 Aug, 2019, 11:23 BST Cyxone's CEO Kjell G. Stenberg Acquires Additional Shares in the Company

Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that the company's CEO Kjell G. Stenberg has for private account increased...


02 Aug, 2019, 09:46 BST Cyxone's T20K Shows Favorable Safety and Tolerability in First-in-human Trial

Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that the clinical phase I trial with drug candidate T20K successfully...


19 Jul, 2019, 07:43 BST Cyxone Makes Further Strides With Rabeximod Phase IIb Trial by Signing CRO EGeen Inc.

Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that the company has signed an agreement with EGeen Inc., a clinical...


12 Jul, 2019, 09:32 BST Cyxone Announce Dosing of First Volunteer in T20K's First-in-human Trial

Cyxone (publ.) a Swedish biotech in autoimmune diseases, today announced that the first healthy male volunteer has received the initial dose in its...


05 Jul, 2019, 08:33 BST Cyxone Submits First Application to Start Clinical Phase IIb Trial With Rabeximod

Cyxone (publ), a Swedish biotech in autoimmune diseases, today submitted an application to the Central Ethics Committee (CEC) in Poland for...


01 Jul, 2019, 17:10 BST First Berlin Equity Research Publishes Updated Independent Analysis of Cyxone

Cyxone (publ) announced today that the internationally renowned research company First Berlin Equity Research has published an updated independent...


20 Jun, 2019, 11:50 BST Cyxone Initiates First-in-human Trial With T20K for the Treatment of MS

Cyxone (publ.), a Swedish biotech in autoimmune diseases, today announced that the company starts its first-in-human, phase I, clinical trial with...


23 May, 2019, 15:22 BST Cyxone Submits Application to Start First-in-human Trial With T20K in MS

Cyxone (publ.), a Swedish biotech in autoimmune diseases, today announced that the company has set a date for the application submission for the...


20 Mar, 2019, 09:39 GMT Cyxone Announces Strategic Intent to Position its Drug Candidate T20K in MS as a Prophylactic Agent

Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that preclinical findings support the positioning of its drug candidate T20K ...


04 Feb, 2019, 09:38 GMT Cyxone Announces Issuance of U.S. Divisional Patent for Drug Candidate T20K in MS

Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that the United States Patent and Trademark Office has issued U.S. Patent...


03 Dec, 2018, 16:45 GMT First Berlin Equity Research Publishes Updated Independent Analysis of Cyxone

Cyxone (publ) announced today that the internationally renowned research company First Berlin Equity Research has published an updated independent...


28 Nov, 2018, 08:02 GMT Cyxone Concludes T20K's Preclinical Program Following Positive Results in Toxicology Studies

Cyxone (publ) announced today that the preclinical program for drug candidate T20K in multiple sclerosis (MS) has been concluded following positive...


31 Oct, 2018, 07:44 GMT First Berlin Equity Research Publishes Independent Analysis of Cyxone

Cyxone (publ) announced today that the internationally renowned research house First Berlin Equity Research has published an independent analysis...


23 Oct, 2018, 07:36 BST Cyxone Selects First Clinical Site Ahead of Phase 1 Study With T20K in MS

Cyxone AB (publ) announced today that the company has selected the clinical site that will carry out the drug candidate T20K's first in man study....


01 Jun, 2018, 14:47 BST Cyxone Completes Acquisition of Drug Candidate Rabeximod

Cyxone AB (publ) announced today that the company has decided to complete the acquisition of drug candidate Rabeximod and issue approximately 1.9...


27 Mar, 2018, 13:54 BST Cyxone's Cyclotide Shows Promising Interim Results in IBD Pilot Study

Cyxone announced today that the first phase of their cyclotide pilot study into inflammatory bowel disease (IBD) has been concluded as planned. The...